Altimmune
ALT
128 hedge funds and large institutions have $1.03B invested in Altimmune in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 38 increasing their positions, 35 reducing their positions, and 30 closing their positions.
719% more call options, than puts
Call options by funds: $60M | Put options by funds: $7.33M
61% more capital invested
Capital invested by funds: $640M → $1.03B (+$391M)
20% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 30
5% more funds holding
Funds holding: 122 → 128 (+6)
9% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7.09% less ownership
Funds ownership: 102.32% → 95.24% (-7.1%)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$28.3M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.7M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$12.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
| 5 |
Jennison Associates
New York
|
+$8.39M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Tudor Investment Corp
Stamford,
Connecticut
| – | -$238K | -18,607 | Closed |
|
|
PP
152
PDT Partners
New York
| – | -$216K | -16,915 | Closed |
|
|
TI
153
Telemetry Investments
New York
| – | -$185K | -14,500 | Closed |
|
|
LP
154
LMR Partners
London,
United Kingdom
| – | -$181K | -14,139 | Closed |
|
|
FRM
155
Fox Run Management
Greenwich,
Connecticut
| – | -$164K | -12,823 | Closed |
|
|
DFCM
156
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$22K | -1,696 | Closed |
|
|
CHA
157
Carmichael Hill & Associates
Gaithersburg,
Maryland
| – | -$9K | -729 | Closed |
|
158
Acadian Asset Management
Boston,
Massachusetts
| – | +$11 | +1 | New |
|
ALT Hedge Fund Activity: Q4 2022 in Review
128 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2022, worth a combined $1.03B — up 61% from $640M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ALT positions and 30 closed out — a net gain of 6 holders — while 38 added to existing stakes and 35 trimmed.
The largest buyer was State Street, adding an estimated $28.3M. The largest seller was Janus Henderson Group, cutting an estimated $49.5M.
- 128 institutional investors held Altimmune (ALT) as of Q4 2022, up from 122 in Q3 2022.
- Funds reported $1.03B of Altimmune stock for Q4 2022, up 61% quarter-over-quarter.
- 36 funds opened new Altimmune positions in Q4 2022 and 30 closed out, a net change of +6 holders.
- The largest Altimmune buyer in Q4 2022 was State Street, an estimated $28.3M added.
- The largest Altimmune seller in Q4 2022 was Janus Henderson Group, an estimated $49.5M sold.
Based on aggregated 13F filings for Q4 2022.